Glenmede Trust’s Ironwood Pharmaceuticals IRWD Stock Holding History

Glenmede Trust’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,395,983	Closed	-$9.1M	–	1408
2024 Q2	$9.1M	Buy	1,395,983 +5,356	+0.4%	+$37.9K	0.05%	365
2024 Q1	$12.1M	Buy	1,390,627 +98,199	+8%	+$1.19M	0.06%	335
2023 Q4	$14.8M	Sell	1,292,428 -32,307	-2%	-$320K	0.08%	270
2023 Q3	$12.8M	Buy	1,324,735 +273,689	+26%	+$2.68M	0.07%	289
2023 Q2	$11.1M	Buy	1,051,046 +2,033	+0.2%	+$21.9K	0.06%	319
2023 Q1	$11M	Buy	1,049,013 +11,347	+1%	+$127K	0.06%	319
2022 Q4	$12.9M	Sell	1,037,666 -127,542	-11%	-$1.45M	0.08%	286
2022 Q3	$12.1M	Sell	1,165,208 -139,705	-11%	-$1.58M	0.08%	275
2022 Q2	$15M	Sell	1,304,913 -141,986	-10%	-$1.67M	0.09%	256
2022 Q1	$18.2M	Buy	1,446,899 +367,073	+34%	+$4.21M	0.09%	270
2021 Q4	$12.6M	Sell	1,079,826 -12,784	-1%	-$157K	0.06%	348
2021 Q3	$14.3M	Sell	1,092,610 -5,203	-0.5%	-$67.2K	0.07%	299
2021 Q2	$14.1M	Sell	1,097,813 -2,488	-0.2%	-$28.5K	0.07%	294
2021 Q1	$12.3M	Buy	1,100,301 +288,838	+36%	+$3.05M	0.07%	305
2020 Q4	$9.24M	Sell	811,463 -88,502	-10%	-$968K	0.05%	334
2020 Q3	$8.09M	Buy	899,965 +897,937	+44,277%	+$8.92M	0.05%	330
2020 Q2	$20K	Hold	2,028	–	–	﹤0.01%	1596
2020 Q1	$26K	Hold	2,028	–	–	﹤0.01%	1954
2019 Q4	$26K	Hold	2,028	–	–	﹤0.01%	1954
2019 Q3	$17	Hold	2,028	–	–	﹤0.01%	2121
2019 Q2	$22	Sell	2,028 -393	-16%	-$4.4K	﹤0.01%	2026
2019 Q1	$27	Sell	2,421 -35	-1%	-$391	﹤0.01%	1958
2018 Q4	$21	Buy	2,456 +33	+1%	+$379	﹤0.01%	1967
2018 Q3	$37K	Hold	2,423	–	–	﹤0.01%	1334
2018 Q2	$39K	Sell	2,423 -96	-4%	-$1.42K	﹤0.01%	1527
2018 Q1	$31K	Hold	2,519	–	–	﹤0.01%	1805
2017 Q4	$31K	Hold	2,519	–	–	﹤0.01%	1805
2017 Q3	$33K	Hold	2,519	–	–	﹤0.01%	1798
2017 Q2	$35K	Hold	2,519	–	–	﹤0.01%	1729
2017 Q1	$35K	Hold	2,519	–	–	﹤0.01%	1729
2016 Q4	$32K	Sell	2,519 -108	-4%	-$1.36K	﹤0.01%	1748
2016 Q3	$34K	Buy	2,627 +108	+4%	+$1.26K	﹤0.01%	1754
2016 Q2	$27K	Hold	2,519	–	–	﹤0.01%	1792
2016 Q1	$23K	Buy	2,519 +131	+5%	+$1.08K	﹤0.01%	1781
2015 Q4	$23K	Hold	2,388	–	–	﹤0.01%	1823
2015 Q3	$20K	Hold	2,388	–	–	﹤0.01%	1900
2015 Q2	$24K	Hold	2,388	–	–	﹤0.01%	1838
2015 Q1	$32K	Hold	2,388	–	–	﹤0.01%	1815
2014 Q4	$30K	Hold	2,388	–	–	﹤0.01%	1902
2014 Q3	$25K	Hold	2,388	–	–	﹤0.01%	1895
2014 Q2	$30K	Hold	2,388	–	–	﹤0.01%	1768
2014 Q1	$24K	Hold	2,388	–	–	﹤0.01%	1853
2013 Q4	$23K	Hold	2,388	–	–	﹤0.01%	1817
2013 Q3	$23K	Hold	2,388	–	–	﹤0.01%	1769
2013 Q2	$19K	Buy	+2,388	New	+$28.9K	﹤0.01%	1738

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Trust's IRWD Position: Q3 2024 in Review

Glenmede Trust sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2024, closing a stake of 1,395,983 shares — an estimated $9.1M sold.

Glenmede Trust first reported a position in IRWD in Q2 2013 and held it in 45 quarters. The position peaked at $18.2M in Q1 2022. 221 funds tracked by Wall St. Rank hold IRWD as of Q3 2024.

Glenmede Trust reported no remaining Ironwood Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Glenmede Trust sold 1,395,983 Ironwood Pharmaceuticals shares in Q3 2024, an estimated $9.1M.
Glenmede Trust first reported a position in Ironwood Pharmaceuticals in Q2 2013 and held it in 45 quarters.
Glenmede Trust's Ironwood Pharmaceuticals position peaked at $18.2M in Q1 2022.
221 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2024.

Based on Glenmede Trust's 13F filing for Q3 2024, filed 13 Nov 2024.